NASDAQ$PHAT
Phathom Pharmaceuticals Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Phathom reported first quarter 2022 results, highlighted by FDA approval for VOQUEZNA TRIPLE and DUAL PAKs and a revenue interest financing agreement.
Phathom Pharmaceuticals reported a net loss of $40.7 million for the first quarter of 2022. The company received FDA approval for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK and strengthened its balance sheet with a revenue interest financing agreement.
- Received FDA approval for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for H. pylori infection treatment.
- Signed a revenue interest financing agreement for up to $260 million in non-dilutive financing.
- Commenced a Phase 3 NERD development program with the initiation of a pivotal Phase 3 vonoprazan daily dosing trial.
- Appointed Molly Henderson as Chief Financial and Business Officer and Frank Karbe to its Board of Directors.
Headline financials
Revenue & EPS history
Phathom · Revenue · Quarterly
$58.3M
Forward guidance
Phathom expects to launch vonoprazan-based therapies for H. pylori in Q3 2022 and believes it has sufficient capital to fund operations through 2024.
Tailwinds
- Planned launch of vonoprazan-based therapies for the treatment of H. pylori infection in the third quarter of 2022.
- Initiation of a Phase 3 on-demand dosing trial for NERD.
- Availability of additional funds under revenue interest financing agreement.
- Availability of additional funds under the loan agreement with Hercules Capital.
- Sufficiency of capital to fund the Company’s operations through 2024.
Headwinds
- Inherent risks of clinical development of vonoprazan.
- Dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing.
- Regulatory developments in the United States and foreign countries.
- Ability to successfully launch and commercialize vonoprazan.
- Unexpected adverse side effects or inadequate efficacy of vonoprazan.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-2.2%
Avg return
Earnings day
-5.3%
Avg return
5 days after
-0.4%
Avg return
30 days after
42%
11 / 26 earnings
Positive
+10.0%
Q1 2023
Best reaction
-22.8%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.9% | +6.9% | -18.6% | |
| Q4 2025 | +9.9% | -10.3% | -14.1% | |
| Q3 2025 | -1.8% | +8.1% | +9.8% | |
| Q1 2025 | -21.7% | -44.1% | -0.9% | |
| Q4 2024 | -3.0% | -21.2% | -19.7% | |
| Q3 2024 | -6.3% | -47.1% | -50.0% | |
| Q2 2024 | +8.7% | +12.6% | +63.9% | |
| Q1 2024 | -5.6% | +2.9% | +5.0% | |
| Q4 2023 | -8.7% | -16.0% | +13.4% | |
| Q3 2023 | -4.0% | -9.2% | +7.8% | |
| Q2 2023 | +3.0% | +2.0% | -15.8% | |
| Q1 2023 | +10.0% | +5.0% | +8.3% | |
| Q4 2022 | -7.1% | -10.0% | -29.9% | |
| Q3 2022 | -9.8% | +4.0% | +5.3% | |
| Q2 2022 | -22.8% | -20.1% | -3.6% | |
| Q1 2022 | -6.3% | -10.5% | -19.7% | |
| Q4 2021 | +2.0% | -4.2% | -24.9% | |
| Q3 2021 | +1.7% | -2.4% | -13.7% | |
| Q2 2021 | +1.5% | -0.1% | +6.6% | |
| Q1 2021 | +6.4% | +0.9% | +5.9% | |
| Q4 2020 | +3.6% | +1.9% | +9.8% | |
| Q3 2020 | -8.6% | -3.0% | +12.6% | |
| Q2 2020 | +5.1% | +12.2% | +5.3% | |
| Q1 2020 | -0.9% | -1.4% | +24.1% | |
| Q4 2019 | -3.2% | -3.2% | +13.5% | |
| Q3 2019 | +6.5% | +9.1% | +9.0% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro